The FDA approved olaparib, the first PARP inhibitor, in 2014 for patients with advanced ovarian cancers harboring BRCA mutations.

Authors

• Person: Geller A, Salganicoff A, Burke SP Organization: National Academies Press
  The Biological Basis for Women's Health Through the Lens of ... - NCBI

Sources

• The Biological Basis for Women's Health Through the Lens of ... - NCBI www.ncbi.nlm.nih.gov Geller A, Salganicoff A, Burke SP · National Academies Press via serper

Referenced by nodes (3)

• Ovarian cancer concept
• olaparib concept
• PARP inhibitors concept